The trial will be a multi-center, open-label study involving 75 patients and evaluating multiple INF904 dosing ... data and provide signs of clinical benefit, and to inform the design of a Phase 2b ...
Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...